Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects

Miguel Genebat, Francisco Vera, José Hernández-Quero, Pere Domingo, José M. Guardiola, Onofre Martínez-Madrid, Lorena Martínez, Francisco García De La Llana, Jorge Sánchez-Villegas, Hortensia Álvarez, Ana Mariño, José F. Lluch, María A. Martínez-Pérez, Jorge Marín, Ezequiel Ruiz-Mateos, Manuel Leal

    Research output: Contribution to journalArticleResearchpeer-review

    6 Citations (Scopus)

    Abstract

    Efficacy and tolerability of telaprevir, pegylated interferon and ribavirin combination was assessed in 32 cirrhotic genotype 1 hepatitis C (HCV)-HIV coinfected patients. Undetectability of HCV-RNA was observed in 23/32 (71.9%) patients after 24 weeks. Treatment failure was observed in 9/32 subjects: four of them (45.5%) failed triple therapy due to virological rebound, while 5 patients (55.5%) experienced drug-related side effects driving to treatment interruption. These data suggest that telaprevir-containing triple therapy should be considered for treatment of genotype 1 HCV in HIV coinfected patients with liver cirrhosis, although a close vigilance is required because of potential drug-related side effects. © 2014 Elsevier B.V.
    Original languageEnglish
    Pages (from-to)59-61
    JournalAntiviral Research
    Volume104
    Issue number1
    DOIs
    Publication statusPublished - 1 Apr 2014

    Keywords

    • Hepatitis C virus
    • HIV
    • Liver cirrhosis
    • Telaprevir

    Fingerprint Dive into the research topics of 'Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects'. Together they form a unique fingerprint.

  • Cite this

    Genebat, M., Vera, F., Hernández-Quero, J., Domingo, P., Guardiola, J. M., Martínez-Madrid, O., Martínez, L., De La Llana, F. G., Sánchez-Villegas, J., Álvarez, H., Mariño, A., Lluch, J. F., Martínez-Pérez, M. A., Marín, J., Ruiz-Mateos, E., & Leal, M. (2014). Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects. Antiviral Research, 104(1), 59-61. https://doi.org/10.1016/j.antiviral.2014.01.019